dNovo
DefunctYC S18San Francisco, US · Founded 2018 · 4 employees · 2 known investors
dNovo develops direct reprogramming technology to convert skin, blood, or fat cells into new stem cells, targeting age-related stem cell depletion. The company aims to address aging through cellular regeneration for consumers.
Also known as dNovo Bio
Founders & leadership· Y Combinator alumni (S18)
dNovo was founded in 2018 by Ernesto Lujan.
Investors · 2
Company profile
researched Aug 2026dNovo is a biotechnology company based in the California Bay Area that develops direct reprogramming technology to convert a person's skin, blood, or fat cells into new stem cells, with the stated aim of replacing the functional stem cells lost with age. Its first application area is hair loss, which the company frames as a hair stem cell loss problem driven by dihydrotestosterone (DHT)-induced male pattern baldness and age-associated hair miniaturization, conditions in which hair stem cells are killed or converted into non-hair-producing cells.
The company's proposed treatment pathway uses a small skin sample or a few drops of blood from the patient, to which dNovo's proprietary reprogramming factors are applied to generate personalized, immune-compatible hair-producing cells. Those cells are then seeded onto the scalp, with hair growth anticipated within one to three months of treatment. In addition to hair stem cells, dNovo has worked on reprogramming human dermal papilla cells, the signaling cells of the hair follicle that are also lost when a follicle is fully depleted. The reprogramming technology is described as patent pending and was developed by a team of PhD- and MD-trained scientists from Stanford, Harvard, and Caltech.
Founding story
dNovo was founded in the second quarter of 2018 to address age-associated stem cell loss, choosing hair loss as its first target on the basis that no other group was directly addressing the underlying loss of hair stem cells. The company joined Y Combinator's summer 2018 batch, which it credits with accelerating the commercialization of its direct reprogramming technology.
Business model
dNovo positions itself as bringing a personalized, autologous cell therapy to market: patient cells would be collected at the company's onsite facility, reprogrammed with its proprietary factors into hair-producing cells, and then grafted onto the patient's scalp.
Traction
Reported preclinical milestones include generation of human hair stem cells (2019), demonstrated hair growth from reprogrammed human hair stem cells transplanted into hair-deficient mice (2020), and generation of human dermal papilla cells (2021). The company describes the technology as patent pending and has not published clinical results in the available material.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
dNovo differentiates itself from existing hair loss options by arguing that current solutions only slow or disguise hair loss without treating the underlying stem cell loss, while earlier attempts to generate replacement hair stem cells have largely been unsuccessful. It has received coverage in Fortune, MIT Technology Review, Mashable, and the Silicon Valley Business Journal, as well as German-, Spanish-, Chinese-, and Japanese-language outlets, in the context of biotech startups pursuing balding reversal.
The company's claim to differentiation is treating the root cause of hair loss rather than its symptoms, by generating new personalized hair stem cells and dermal papilla cells from the patient's own skin or blood using its patent-pending direct reprogramming factors, yielding cells said to be compatible with the patient's immune system.
Technology
The core technology is direct reprogramming: proprietary reprogramming factors are applied to somatic cells (skin, blood, or fat) to convert them into stem cells, bypassing the need for donor material and producing cells that are autologous and therefore immune-compatible. The company reports having built reprogramming systems for two hair follicle cell types, human hair stem cells and human dermal papilla cells, and states that in both cases the reprogrammed cells reactivate the native genetic circuitry and perform biochemically like their native counterparts. A grafting and transplantation protocol was optimized to seed the reprogrammed cells onto skin, and efficacy was tested in hair-deficient mice. The reprogramming technology is described as patent pending.
Go-to-market
People experiencing hair loss, specifically from DHT-driven male pattern baldness and age-associated hair miniaturization; longer term, the company frames its technology as addressing age-related stem cell depletion more broadly.
Geography
Based in the California Bay Area / Silicon Valley, United States.
History
After its 2018 founding and participation in Y Combinator's 2018 summer class, dNovo reported in the third quarter of 2019 that it had assembled its direct reprogramming system and generated human hair stem cells that reactivated the genetic circuitry of native hair stem cells and behaved biochemically as expected. In the fourth quarter of 2020, the company developed an optimized transplantation and grafting procedure and reported that its reprogrammed human cells produced hair in hair-deficient mice, with sprouting at three weeks and visible new hair at the treatment site by the second month. In the second quarter of 2021, dNovo reported generating human dermal papilla cells with the same reprogramming approach. The company also emerged from stealth with a press release describing its candidate approach to hair loss.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Competitors · 1
by search overlap
Companies competing with dNovo for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 5
launches, deals, and filingsdNovo reported developing a reprogramming system to generate human dermal papilla cells, the signaling center for hair stem cells (patent pending).
dNovo issued a press release announcing its emergence from stealth with a potential cure for hair loss.
Reprogrammed human hair stem cells were grafted using an optimized transplantation procedure into hair-deficient mice; hair sprouted at three weeks and new hair was visible at the treatment site by the second month.
dNovo reported assembling its direct reprogramming system and generating human hair stem cells that reactivated native hair stem cell genetic circuitry (patent pending).
dNovo participated in Y Combinator's 2018 summer class following its founding in Q2 2018.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 1
primary sources listed
- dNovodnovobio.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does dNovo do?
- dNovo is a Bay Area biotech using direct cell reprogramming to regenerate hair stem cells and treat hair loss.
- Who founded dNovo?
- dNovo was founded by Ernesto Lujan in 2018.
- Who are dNovo's investors?
- dNovo's investors include Flucas Ventures, Y Combinator.
- Where is dNovo headquartered?
- dNovo is headquartered in San Francisco, US.